RxDoctor Payments DataLook up a doctor →

William Dowling, MD

Urology · Baltimore, MDNPI 1407808991

Payments from drug & device makers

$32,950in general payments, 2019–2025

Across 457 payments — averaging $72.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma Global Development$20K
  • SN Holdings, LLC$2K
  • AbbVie$1K
  • Sumitomo Pharma America, Inc.$1K
  • Johnson & Johnson$761
  • Pfizer$760
  • plus $7K from 47 others

What the payments were for

  • Speaking & faculty fees$1121%
  • Travel & lodging$1,51912%
  • Food & beverage$11,51488%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,950 in reported general payments places this provider in the 85th percentile of 274 urology providers in Maryland.

See all urology providers in Maryland

Medicare billing

Part B allowed, 2024
$369,322
Medicare patients
1,082
Services billed
7,624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron71$65,157
MyrbetriqMirabegron44$46,605
Tamsulosin Hcl708$10,219
Finasteride379$8,069
Alfuzosin Hcl ErAlfuzosin Hcl62$2,349
Dutasteride45$1,585
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst91$1,285
Cefdinir123$1,042
Testosterone18$501
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim46$230
Terazosin Hcl11$189
Levofloxacin57$151
Ciprofloxacin Hcl17$106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$1,068$65,15771 claims
Astellas Pharma US IncMyrbetriq$433$46,60544 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 274 urology providers in Maryland.

Other urology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →